8-K current report · filed Nov 3, 2026

Tevogen Bio Holdings Inc. (TVGN) 8-K Current Report: November 3, 2026

Item 1.01Item 2.03Item 3.02Item 5.02TVGN overview

Short answer

Tevogen Bio Holdings Inc. (TVGN) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 5.02 (Departure/Election of Directors or Officers). Borrowing window extended to May 31, 2029, with post-amendment facility availability capped at $28.6 million.

Tevogen Bio Holdings Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Borrowing window extended to May 31, 2029, with post-amendment facility availability capped at $28.6 million
  • $7.4 million principal plus $177,880 accrued interest repaid through 1,023,733 shares at $7.40 per share
  • Debt eliminated under the agreement, but repayment increased equity dilution rather than using cash
  • Up to approximately 4.99 million additional shares potentially issuable if full facility borrowing and PIPE conditions occur
  • Fixed 9.99% lender ownership limit and 19.99% issuance cap constrain near-term share accumulation and dilution

Item 3.02 · Unregistered Sales of Equity Securities

  • Potential equity issuance to lender for debt repayment, creating dilution risk for TVGN shareholders
  • Pre-funded warrants may substitute for shares, preserving lender conversion economics while deferring share issuance
  • Registration statement due within 15 calendar days after Principal Shares issuance, enabling lender resale
  • Securities issued privately under Section 4(a)(2) and/or Rule 506, limiting immediate public offering requirements

Item 5.02 · Departure/Election of Directors or Officers

  • CEO Ryan Saadi received 50,000,000 restricted shares, creating substantial potential dilution if the performance condition is achieved
  • Vesting requires $1.0 billion aggregate revenue by December 31, 2031, aligning compensation with a long-term growth target
  • Saadi can vote the unvested shares, increasing his control to approximately 90.9% of voting power across 67,880,267 outstanding shares
  • Shares are forfeited upon failure to meet the target, service termination, prohibited transfer, or certain change-in-control outcomes
  • Award reinforces founder control while leaving economic ownership contingent on company performance

Other items in this filing:

  • Item 2.03: Creation of a Direct Financial Obligation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tevogen Bio Holdings Inc. 8-K filings

Get the next TVGN 8-K as it lands

Follow TVGN for push alerts, or ask the research agent what this filing means.